Protocol Expansion to Ages 10+ Aligned with FDA Guidance, Broadening Patient Population SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announces alignment with the U.S. Food and Drug... Read More

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025 at 9:00 a.m. Eastern time. A live webcast... Read More

SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that on August 28, 2025, two new employees were granted inducement awards consisting of stock options to purchase an aggregate of 20,013 shares of common stock. Each... Read More

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during September: Cantor Fitzgerald Global Healthcare Conference 2025 in New York... Read More

Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 STRENGTH trial to focus on durable weight loss as a monotherapy and in combination with GLP-1RA. Anticipated expansion of Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia... Read More

In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment. ARD-201 was also associated with attenuated weight regain after discontinuation of tirzepatide. In combination with low-dose tirzepatide, ARD-201 improved weight loss compared to high dose tirzepatide alone. Aardvark plans two separate Phase 2 clinical trials for ARD-201: Phase 2 POWER... Read More

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that between July 8-14, 2025, two new employees were granted inducement awards consisting of stock options to purchase an aggregate of 10,372 shares of common stock. Each... Read More

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place... Read More

Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule... Read More

Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel,... Read More

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during May: Bank of America Global Healthcare Conference 2025 in Las Vegas Presentation:... Read More

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16-point HQ-CT reduction, with an average reduction of approximately 8 points among subjects that followed trial protocol) observed during the 28-day dosing period. DEXA scans analysis from the PWS Phase 2 trial data measuring... Read More